摘要
目的:探究重组人干扰素α2b雾化吸入治疗小儿呼吸道腺病毒感染的临床效果及安全性。方法:选取2023年2月—2025年2月于惠州卫生职业技术学院附属医院接受诊治的60例呼吸道腺病毒感染患儿,以随机数字表法划分为对照组(n=30,常规治疗)和观察组(n=30,在对照组基础上联合重组人干扰素α2b治疗)。比较两组临床症状改善情况、血常规指标、心肌酶指标、临床疗效及不良反应。结果:观察组退热时间以及鼻塞流涕、咽部疼痛、咳嗽消失时间相比于对照组均更短(P<0.001);治疗后,观察组白细胞计数、淋巴细胞占比、乳酸脱氢酶、肌酸激酶、肌酸激酶同工酶水平均比对照组低(P<0.001);观察组治疗总有效率比对照组更高(P=0.044);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:将重组人干扰素α2b应用在呼吸道腺病毒感染患儿临床治疗中能够促进患儿临床症状改善,减轻炎性反应及心肌损伤,有效性及安全性均较高。
Objective:To explore the clinical efficacy and safety of nebulized inhalation of recombinant human interferonα2b in the treatment of respiratory adenovirus infection in children.Methods:Sixty children with respiratory adenovirus infection who were diagnosed and treated at Huizhou Affiliated Hospital of Health Vocational and Technical College from February 2023 to February 2025 were selected and divided into the control group(n=30,conventional treatment)and the observation group(n=30,combined with recombinant human interferonα2b treatment on the basis of the control group)by the random number table method.The improvement of clinical symptoms,blood routine indicators,myocardial enzyme indicators,clinical efficacy and adverse reactions were compared between the two groups.Results:The time for fever reduction and the disappearance time of nasal congestion and runny nose,pharyngeal pain and cough in the observation group were all shorter than those in the control group(P<0.001).After treatment,the white blood cell count,lymphocyte proportion,lactate dehydrogenase,creatine kinase,and creatine kinase isoenzyme levels in the observation group were all lower than those in the control group(P<0.001).The total effective rate of treatment in the observation group was higher than that in the control group(P=0.044).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application of recombinant human interferonα2b in the clinical treatment of children with respiratory adenovirus infection can promote the improvement of clinical symptoms in children,reduce inflammatory responses and myocardial injury,and has high efficacy and safety.
作者
陈志宏
Chen Zhihong(Huizhou Affiliated Hospital of Health Vocational and Technical College,Huizhou 516000,Guangdong Province,China)
出处
《中外医药研究》
2025年第21期20-22,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
基金
2024年惠州市医疗卫生领域科技计划项目(编号:2024CZ10115)。
关键词
重组人干扰素Α2B
雾化吸入
呼吸道腺病毒感染
小儿
Recombinant human interferonα2b
Nebulized inhalation
Respiratory adenovirus infection
Children
